drugset / Trial / NCT06326736
Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer
Phase 0
Recruiting
12 enrolled
Jinling Hospital, China
Jiangsu Synthgene Biotechnology Co.Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of treating pancreatic cancer with surgery to remove cancerour tissue, followed by camrelizumab and a personalized cancer mRNA vaccines.
Timeline
- Start
- 2024-04
- Primary completion
- 2025-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | — | — |
| Subject | SJ-Neo006 | Messenger RNA (mRNA) | — | — |
| Background | Gemcitabine | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | — | — |